MedTrace Logo

Immune Cell Therapy for Advanced Solid Tumors

NCT07260058 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-12-02

No results posted yet for this study

Summary

The autologous immune cell induction technology used in this project involves transforming peripheral blood mononuclear cells (PBMC) into autologous DC cells, NK cells, CIK cells and other immune cells through cytokine induction, and then re-administering them to the patients. This therapy utilizes biotechnology to culture the immune cells of cancer patients in vitro and then re-infuse them back into the body, stimulating and enhancing the body's own immune function, killing and inhibiting cancer cells, eliminating small and residual lesions, or achieving the goal of treating cancer by significantly inhibiting the proliferation of residual cancer cells.

Conditions

  • Lung Cancer (Locally Advanced or Metastatic)
  • Liver Cancer (Locally Advanced or Metastatic)
  • Colorectal Cancer (Locally Advanced or Metastatic)
  • Breast Cancer (Locally Advanced or Metastatic)
  • Advanced Solid Tumors

Interventions

BIOLOGICAL

Autologous immune Cells

1. Autologous DC-CIK Cells：Dendritic Cells (DC) and Cytokine-Induced Killer (CIK) cells are manufactured ex vivo from the participant's own peripheral blood mononuclear cells (PBMCs). DC cells (\>5x10⁶ cells) are administered via subcutaneous injection. CIK cells (\>5x10⁹ cells) are administered via intravenous infusion. 2. Autologous NK Cells：Natural Killer (NK) cells are manufactured ex vivo from the participant's own peripheral blood mononuclear cells (PBMCs). NK cells (≥3x10⁹ cells) are administered via intravenous infusion.

DRUG

Standard chemotherapy

Investigator's choice of standard chemotherapy regimen(s) appropriate for the participant's specific type of advanced solid tumor (lung, liver, colorectal, or breast cancer), administered according to local clinical practice.

Sponsors & Collaborators

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wei Minjie, Doctor · Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2027-06-30
Completion
2027-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07260058 on ClinicalTrials.gov